J.P. Morgan upgrades Biogen to 'overweight', shares rise 

By Reuters News

** Shares of drug maker Biogen BIIB.O rise nearly 2% to $230.35 premarket

** J.P. Morgan upgrades stock rating to "overweight" from "neutral"; raises PT to $300 from $210, which represents ~33% upside to the stock's last close on Friday

** Brokerage sees several key 2027 catalysts, including felzartamab for antibody-mediated rejection (AMR) in organ transplants, a potential $2 billion-plus market opportunity

** "We see BIIB as one of the more attractive names to own heading into 2027 as the company evolves beyond just a Leqembi story", (the Alzheimer's disease treatment)

** 38 analysts rate stock "buy" on average; median PT is $242 - data compiled by LSEG

** Up to last day's close, the stock had risen 28.25% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.